Oncology Radiopharmaceuticals are widely used to Treat Cancer Cells
![]() |
| Oncology Radiopharmaceuticals |
Oncology Radiopharmaceuticals agents are designed to penetrate cancer cells and break down
naturally once they attach to a cancer cell. The radioactive compound then
decays, causing irreparable damage to the DNA of nearby cells. Cancer cells are
particularly susceptible to DNA damage from radiation, and a single molecule of
radiopharmaceutical can kill up to 10 cells around a bound cell.
Radiation
therapy is an important part of cancer treatment, with the National Cancer
Institute estimating that nearly half of all cancer patients will receive some
form of radiation therapy during their lifetimes. In radiation therapy, a beam
of high-energy radiation is directed at the cancerous growth in order to kill
it. Recently, however, oncologists have shown a growing interest in using
radiopharmaceuticals, which are drugs that contain radioactive particles
attached to them. These drugs can accurately target cancer cells and help treat
cancer. Although these drugs have been around for decades, it has taken some
time to make its way into the real world.
Oncologists use
these radiopharmaceuticals in combination with other treatments. One of the
examples of such combinations is the use of lutetium-177 and galium-68 in the
treatment of neuroendocrine tumors. Oncology
Radiopharmaceuticals can be injected directly into the bloodstream,
taken as a liquid, or placed into the body cavity to target tumors in these
regions. Further, these radiopharmaceuticals have other applications in radiology,
including PET scans.
Currently,
several new oncology radiopharmaceuticals have been launched in the market,
with several others in various stages of development. Some notable examples
include Axumin from Blue Earth Diagnostics for the treatment of recurrent
prostate cancer, and Gallium-68 dotatate, which is approved to treat rare
endocrine tumors. These agents are also being used in clinical trials and have
already surpassed the marketed doses of the latter in some cases. Successful
clinical trials require the validation of radiopharmaceuticals that show high
efficacy. To ensure their efficacy, radiopharmaceuticals must demonstrate high
specificity and high selectivity. Successful validation can shorten the drug
development timeline and increase the predictability of the results. In
addition, small sample sizes are necessary for the evaluation of
radiopharmaceutical efficacy. So, when selecting a new radiopharmaceutical for
a clinical trial, consider the following guidelines.
The development
of radiopharmaceuticals is an increasingly important area of research for the
life sciences industry. While there are already several radiopharmaceuticals
for cancer treatment, there are only a few that have reached commercial
success. In addition to oncology studies, radiolabelled compounds for injection
are increasingly used in drug development studies. Injection of radiotracers
allows for early phase I clinical trials and is also an efficient way to test
drugs before the development process starts. The objective of this document is
to describe the production and safety testing procedures of oncology
radiotracers.

Comments
Post a Comment